| __timestamp | Apellis Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 612613000000 |
| Thursday, January 1, 2015 | 6356782 | 650773000000 |
| Friday, January 1, 2016 | 4303743 | 619061000000 |
| Sunday, January 1, 2017 | 10463151 | 628106000000 |
| Monday, January 1, 2018 | 22639184 | 717599000000 |
| Tuesday, January 1, 2019 | 67046483 | 964737000000 |
| Wednesday, January 1, 2020 | 139401000 | 875663000000 |
| Friday, January 1, 2021 | 176771000 | 886361000000 |
| Saturday, January 1, 2022 | 277163000 | 997309000000 |
| Sunday, January 1, 2023 | 500815000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Apellis Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Takeda's SG&A expenses have shown a steady increase, peaking at approximately 1.05 trillion yen in 2023, reflecting a strategic expansion and investment in global markets. In contrast, Apellis Pharmaceuticals, a relatively smaller player, has seen its SG&A expenses grow from a modest 2.9 million dollars in 2014 to a significant 500 million dollars in 2023, marking a staggering increase of over 17,000%. This dramatic rise underscores Apellis's aggressive market penetration and scaling efforts. While Takeda's expenses dwarf those of Apellis, the latter's rapid growth trajectory is noteworthy, highlighting its potential to disrupt the market.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Apellis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Merus N.V.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Geron Corporation